Company news

Arcturus Therapeutics Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19

July 20, 2020

Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

June 30, 2020

Arcturus Therapeutics to be Added to Russell 2000® Index

June 28, 2020

Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

June 10, 2020

Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

June 4, 2020

Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

May 7, 2020

Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

May 6, 2020

Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

May 3, 2020

Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

May 3, 2020

Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate

April 26, 2020

Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

April 15, 2020

Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

April 12, 2020

Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

April 8, 2020

Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

March 26, 2020

Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results

March 10, 2020

Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR Technology™

March 3, 2020

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

February 23, 2020

Arcturus Therapeutics to Present at Two Investor Conferences in March

February 18, 2020

Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer

January 7, 2020

Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia.

December 10, 2019

Arcturus Therapeutics Expands Platform with STARR Technology™

November 6, 2019

Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

November 6, 2019

Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

November 3, 2019

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

October 1, 2019

← Newer news releases

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.